Research programme: Creutzfeldt Jakob disease therapies - Serono

Drug Profile

Research programme: Creutzfeldt Jakob disease therapies - Serono

Alternative Names: iPrP13; Prion inhibitory proteins research programme - Axonyx/Serono

Latest Information Update: 28 Jan 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator New York University
  • Developer Merck Serono; TorreyPines Therapeutics Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Creutzfeldt-Jakob disease

Most Recent Events

  • 22 Mar 2004 Discontinued - Preclinical for Creutzfeldt-Jakob disease in Switzerland (unspecified route)
  • 23 Oct 2000 Prion inhibitory peptides have been licensed to Serono in Switzerland
  • 21 Jun 2000 Ares-Serono is now called Serono
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top